Stoke Therapeutics (NASDAQ:STOK) Price Target Lowered to $20.00 at Canaccord Genuity Group

Stoke Therapeutics (NASDAQ:STOK) had its price objective dropped by analysts at Canaccord Genuity Group from $21.00 to $20.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the stock. Canaccord Genuity Group’s price objective points to a potential upside of 72.41% from the company’s previous close.

Several other equities analysts have also weighed in on the company. Needham & Company LLC reissued a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a research note on Monday. TD Cowen raised shares of Stoke Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, March 26th. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 target price on shares of Stoke Therapeutics in a research note on Tuesday. Wedbush lifted their price target on shares of Stoke Therapeutics from $13.00 to $17.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 26th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Stoke Therapeutics from $6.00 to $13.00 and gave the company a “neutral” rating in a research report on Tuesday, March 26th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Stoke Therapeutics has an average rating of “Moderate Buy” and an average price target of $20.57.

Stoke Therapeutics Price Performance

Shares of NASDAQ:STOK opened at $11.60 on Tuesday. The stock has a market cap of $604.59 million, a price-to-earnings ratio of -4.89 and a beta of 0.82. The company has a 50 day moving average of $10.23 and a 200-day moving average of $6.68. Stoke Therapeutics has a one year low of $3.35 and a one year high of $16.40.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings data on Monday, March 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.02. The business had revenue of $2.80 million during the quarter, compared to the consensus estimate of $3.70 million. Equities research analysts anticipate that Stoke Therapeutics will post -2.28 earnings per share for the current year.

Insider Buying and Selling at Stoke Therapeutics

In related news, CFO Stephen J. Tulipano sold 4,116 shares of the stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $6.10, for a total transaction of $25,107.60. Following the completion of the transaction, the chief financial officer now directly owns 20,746 shares in the company, valued at $126,550.60. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In related news, CFO Stephen J. Tulipano sold 4,116 shares of the firm’s stock in a transaction on Tuesday, March 19th. The shares were sold at an average price of $6.10, for a total value of $25,107.60. Following the completion of the transaction, the chief financial officer now owns 20,746 shares of the company’s stock, valued at $126,550.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Edward M. Md Kaye sold 11,150 shares of Stoke Therapeutics stock in a transaction on Tuesday, March 19th. The shares were sold at an average price of $6.10, for a total transaction of $68,015.00. Following the completion of the sale, the chief executive officer now owns 69,350 shares in the company, valued at $423,035. The disclosure for this sale can be found here. Insiders have sold 3,622,741 shares of company stock valued at $41,935,115 in the last 90 days. 11.30% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of STOK. Lynx1 Capital Management LP acquired a new position in shares of Stoke Therapeutics during the 3rd quarter worth approximately $6,738,000. GSA Capital Partners LLP raised its position in Stoke Therapeutics by 514.7% during the third quarter. GSA Capital Partners LLP now owns 348,069 shares of the company’s stock worth $1,371,000 after acquiring an additional 291,443 shares in the last quarter. Birchview Capital LP raised its position in Stoke Therapeutics by 147.1% during the fourth quarter. Birchview Capital LP now owns 210,000 shares of the company’s stock worth $1,105,000 after acquiring an additional 125,000 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Stoke Therapeutics by 9.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 146,076 shares of the company’s stock valued at $576,000 after acquiring an additional 12,478 shares during the last quarter. Finally, Trexquant Investment LP grew its position in shares of Stoke Therapeutics by 166.9% in the 3rd quarter. Trexquant Investment LP now owns 127,581 shares of the company’s stock valued at $503,000 after acquiring an additional 79,785 shares during the period.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.